Porcine Vaccines

Porcine Vaccines

Global Porcine Vaccines Market to Reach US$3.0 Billion by 2030

The global market for Porcine Vaccines estimated at US$2.2 Billion in the year 2023, is expected to reach US$3.0 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2023-2030. Inactivated Vaccines Technology, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Recombinant Vaccines Technology segment is estimated at 5.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$586.7 Million While China is Forecast to Grow at 8.4% CAGR

The Porcine Vaccines market in the U.S. is estimated at US$586.7 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$634.0 Million by the year 2030 trailing a CAGR of 8.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Porcine Vaccines Market - Key Trends and Drivers Summarized

Porcine vaccines are critical tools in the management and control of infectious diseases in swine populations, safeguarding animal health and enhancing the efficiency of pork production. These vaccines help in preventing a range of diseases, including classical swine fever, porcine reproductive and respiratory syndrome (PRRS), and swine influenza, among others. The importance of porcine vaccines is underscored by the significant economic impacts these diseases can have on the pork industry through losses in productivity and high mortality rates. Effective vaccination programs are essential for maintaining the health of swine herds and ensuring the production of high-quality pork products. Moreover, the use of vaccines in swine helps reduce the need for antibiotics, which is crucial in the fight against antimicrobial resistance. Manufacturers have developed both live attenuated and inactivated vaccines, which can be administered via various routes, including injection, oral, and nasal applications, tailored to maximize efficacy and ease of use in diverse farming environments.

The development and enhancement of porcine vaccines have been influenced heavily by advances in biotechnology and veterinary sciences. Modern diagnostic tools and genetic sequencing techniques have enabled better identification and understanding of swine pathogens, leading to more targeted vaccine development. This precision not only improves the effectiveness of vaccines but also reduces potential side effects, enhancing animal welfare. Another trend is the rise in the use of combination vaccines that target multiple pathogens in a single formulation, simplifying vaccination schedules and reducing stress on animals. Additionally, there is a growing emphasis on the development of thermostable vaccines that do not require refrigeration, making them particularly valuable in rural or under-resourced regions where cold chain infrastructure is lacking. These innovations have expanded the accessibility and impact of vaccination programs worldwide, contributing to the overall health and productivity of swine industries.

The growth in the porcine vaccines market is driven by several factors, including the increasing prevalence of swine diseases, global expansion of pork production, and heightened awareness among farmers about the benefits of vaccination. The spread of intensive pig farming and the consequent rise in disease transmission risks necessitate robust vaccination protocols. Economic growth in emerging markets has led to increased demand for pork, incentivizing producers to invest in health management practices, including vaccination, to boost yields and profitability. Furthermore, regulatory policies promoting animal health and food safety have mandated the use of vaccines in many countries, reinforcing market growth. Advances in vaccine technology, such as the development of DNA vaccines and the use of adjuvants to enhance immune responses, also play a critical role. Collectively, these drivers are shaping a vibrant market landscape, highlighting the importance of continued innovation and adaptation in vaccine development to meet the evolving challenges in swine health management.

Select Competitors (Total 86 Featured) -

• Bimeda Biologicals Inc.
• Boehringer Ingelheim Animal Health USA Inc.
• Ceva Sante Animale
• Elanco Animal Health
• Endovac Animal Health
• ICAR-Indian Veterinary Research Institute (ICAR-IVRI)
• Indian Immunologicals Ltd.
• Laboratorios HIPRA SA (HIPRA)
• Merck Animal Health
• Phibro Animal Health Corporation
• Shandong Sinder Technology Co., Ltd.
• Vaxxinova International
• Vetoquinol S.A.
• Zoetis, Inc.;

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.